who owns the patent for semaglutide Ozempic, Wegovy and Rybelsus: patents behind Novo Nordisk's weight-loss drugs Within weeks of the semaglutide

Symptoms of type A include intellectual disability, developmental delay, abdominal pain, vomiting, fatigue, and acid-base imbalance with increased concentrations of lactic acid (lactic acidosis) and increased concentrations of ketone bodies (ketoacidosis)

According to Novo Nordisk, acute gallstone disease was reported in 1.6 per cent of patients, which led to cholecystitis - or inflammation of the gallbladder - in 0.6 per cent of patients

Some people say they can lose or maintain weight on such tiny doses and others believe the microdoses can help with other health-related factors

Subcutaneous fat shows higher thyroid hormone receptor-1 gene expression than omental fat

However, as with any prescription, its important doctors follow professional guidelines and the principles of evidence-based medicine to ensure patient safety